Victoria Allan

712 total citations
15 papers, 434 citations indexed

About

Victoria Allan is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Oncology. According to data from OpenAlex, Victoria Allan has authored 15 papers receiving a total of 434 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 5 papers in Economics and Econometrics and 4 papers in Oncology. Recurrent topics in Victoria Allan's work include Atrial Fibrillation Management and Outcomes (8 papers), Acute Myocardial Infarction Research (5 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Victoria Allan is often cited by papers focused on Atrial Fibrillation Management and Outcomes (8 papers), Acute Myocardial Infarction Research (5 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Victoria Allan collaborates with scholars based in United Kingdom, France and United States. Victoria Allan's co-authors include Amitava Banerjee, Harry Hemingway, Sreeram V Ramagopalan, Xianying Pan, Xuemei Luo, Jack Mardekian, Juan-Pablo Casas, Xiaoyan Li, Aaron Jenkins and Chris P Gale and has published in prestigious journals such as Journal of the American College of Cardiology, Annals of Oncology and Heart.

In The Last Decade

Victoria Allan

15 papers receiving 428 citations

Peers

Countries citing papers authored by Victoria Allan

Since Specialization

Citations

This map shows the geographic impact of Victoria Allan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victoria Allan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victoria Allan more than expected).

Fields of papers citing papers by Victoria Allan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victoria Allan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victoria Allan. The network helps show where Victoria Allan may publish in the future.

Co-authorship network of co-authors of Victoria Allan

This figure shows the co-authorship network connecting the top 25 collaborators of Victoria Allan. A scholar is included among the top collaborators of Victoria Allan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victoria Allan. Victoria Allan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer 2025 ·Future Oncology ·Apar Kishor Ganti, Ralph B. D’Agostino, Victoria Allan, (unknown), (unknown), Nileesa Gautam, (unknown), (unknown), Wenyan Li, (unknown), (unknown), Elizabeth M. Poole	1
2	Factors associated with non-prescription of oral anticoagulant treatment in non-valvular atrial fibrillation patients with dementia: a CPRD–HES study 2020 ·Age and Ageing ·(unknown), Sophie Graham, Cormac Sammon, Faisal Mehmud, Victoria Allan, Raza Alikhan, Sreeram V Ramagopalan	11
3	Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants 2020 ·Journal of Comparative Effectiveness Research ·Victoria Allan, Sreeram V Ramagopalan, Jack Mardekian, Aaron Jenkins, Xiaoyan Li, Xianying Pan, Xuemei Luo	110
4	Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis 2019 ·BMC Medicine ·Laura Pasea, Sheng‐Chia Chung, Mar Pujades‐Rodríguez, Anoop D Shah, Samantha Alvarez‐Madrazo, Victoria Allan, James Teo, Daniel Bean, Reecha Sofat, Richard Dobson, Amitava Banerjee, Riyaz Patel, Adam Timmis, Spiros Denaxas, Harry Hemingway	17
5	Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study 2019 ·Annals of Oncology ·Fabrice Barlési, A. Dixmier, D. Debieuvre, (unknown), J.B. Auliac, Nicolas Benoît, P. Bombaron, Denis Moro‐Sibilot, Clarisse Audigier-Valette, Bernard Asselain, (unknown), (unknown), Victoria Allan, M. Daumont, (unknown), C. Calvet, M. Pérol	1
6	Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study 2019 ·Annals of Oncology ·M. Pérol, A. Dixmier, Fabrice Barlési, D. Debieuvre, (unknown), J.B. Auliac, Nicolas Benoît, P. Bombaron, Denis Moro‐Sibilot, Bernard Asselain, (unknown), (unknown), (unknown), (unknown), C. Calvet, (unknown), Victoria Allan, Clarisse Audigier-Valette	3
7	Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis 2019 ·EP Europace ·Amitava Banerjee, Victoria Allan, Spiros Denaxas, Anoop D Shah, Dipak Kotecha, Pier D. Lambiase, Jacob Joseph, Lars H. Lund, Harry Hemingway	20
8	IO-synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany 2019 ·Annals of Oncology ·(unknown), Bernard Asselain, Fabrice Barlési, D. Debieuvre, Clarisse Audigier-Valette, A Gröschel, S Gütz, Rüediger Liersch, Denis Moro‐Sibilot, (unknown), M. Pérol, (unknown), Christoph Schulte, H. Schulz, Christian Schumann, Victoria Allan, C. Calvet, Kieran Rothnie, (unknown), Martin Sebastian	2
9	Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases 2018 ·Journal of Comparative Effectiveness Research ·Sreeram V Ramagopalan, Victoria Allan, Stefania Saragoni, Luca Degli Esposti, (unknown), Valentina Perrone, Stefano Buda, (unknown), (unknown), (unknown), (unknown)	6
10	NOACS VERSUS WARFARIN USE IN THE MANAGEMENT OF ATRIAL FIBRILLATION PATIENTS 2017 ·Journal of the American College of Cardiology ·(unknown), Victoria Allan, (unknown)	1
11	Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? 2017 ·Thrombosis and Haemostasis ·Victoria Allan, Shohreh Honarbakhsh, Juan-Pablo Casas, (unknown), Ross J. Hunter, Richard J. Schilling, Pablo Perel, Katherine I. Morley, Amitava Banerjee, Harry Hemingway	114
12	Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care 2016 ·Heart ·Victoria Allan, Amitava Banerjee, Anoop D Shah, Riyaz Patel, Spiros Denaxas, Juan-Pablo Casas, Harry Hemingway	29
13	Trends in hospital treatments, including revascularisation, following acute myocardial infarction, 2003–2010: a multilevel and relative survival analysis for the National Institute for Cardiovascular Outcomes Research (NICOR) 2014 ·Heart ·Chris P Gale, Victoria Allan, Brian A. Cattle, Alistair S. Hall, Robert West, Adam Timmis, Huon Gray, John Deanfield, Keith A.A. Fox, Richard Feltbower	76
14	Age-dependent improvements in survival after hospitalisation with acute myocardial infarction: an analysis of the Myocardial Ischemia National Audit Project (MINAP) 2013 ·Age and Ageing ·Oras Alabas, Victoria Allan, (unknown), Richard Feltbower, Chris P Gale	34
15	026 TRENDS IN IN-HOSPITAL TREATMENTS, INCLUDING REVASCULARISATION, FOLLOWING ACUTE MYOCARDIAL INFARCTION, 2003–2010: A MULTI-LEVEL AND RELATIVE SURVIVAL ANALYSIS FOR THE NATIONAL INSTITUTE FOR CARDIOVASCULAR OUTCOMES RESEARCH (NICOR) 2013 ·Heart ·Chris P Gale, Victoria Allan, Brian A. Cattle, Alistair S. Hall, Robert West, (unknown), (unknown), (unknown), Keith A.A. Fox, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact